Medical experts are urging the public to receive bivalent boosters, claiming "cross-reactivity" will provide protection against the XBB.1.5 variant. Only 15% of the eligible US population has received the new booster, with higher rates among those over 65. The technical nomenclature "XBB" refers to a cross-recombinant of BA.2.10 and BA.2.75, though AI tools like ChatGPT struggle to provide real-time updates on these specific variants.
